Search Result

Results for "

JAK2-STAT3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (7) Aldose Reductase (1) Amyloid-β (4) Apoptosis (20) Arginase (1) Autophagy (6) Bacterial (1) c-Myc (1) Caspase (1) COX (4) Cytochrome P450 (2) Deubiquitinase (1) Drug Derivative (1) Endogenous Metabolite (3) ERK (3) HIF/HIF Prolyl-Hydroxylase (3) IKK (2) Interleukin Related (5) JAK (37) JNK (4) Keap1-Nrf2 (1) MMP (1) Monoamine Oxidase (2) mTOR (2) Na+/K+ ATPase (1) nAChR (2) Necroptosis (1) NF-κB (5) NO Synthase (7) p38 MAPK (7) PI3K (8) Polo-like Kinase (PLK) (1) Reactive Oxygen Species (ROS) (6) Reference Standards (7) RIP kinase (1) Sirtuin (1) SOD (1) STAT (31) TNF Receptor (3) VEGFR (3)
By Research Areas:	Cancer (26) Cardiovascular Disease (10) Infection (3) Inflammation/Immunology (19) Metabolic Disease (3) Neurological Disease (11)

By Targets:

Akt (7)

Aldose Reductase (1)

Amyloid-β (4)

Apoptosis (20)

Arginase (1)

Autophagy (6)

Bacterial (1)

c-Myc (1)

Caspase (1)

COX (4)

Cytochrome P450 (2)

Deubiquitinase (1)

Drug Derivative (1)

Endogenous Metabolite (3)

ERK (3)

HIF/HIF Prolyl-Hydroxylase (3)

IKK (2)

Interleukin Related (5)

JAK (37)

JNK (4)

Keap1-Nrf2 (1)

MMP (1)

Monoamine Oxidase (2)

mTOR (2)

Na+/K+ ATPase (1)

nAChR (2)

Necroptosis (1)

NF-κB (5)

NO Synthase (7)

p38 MAPK (7)

PI3K (8)

Polo-like Kinase (PLK) (1)

Reactive Oxygen Species (ROS) (6)

Reference Standards (7)

RIP kinase (1)

Sirtuin (1)

SOD (1)

STAT (31)

TNF Receptor (3)

VEGFR (3)

By Research Areas:

Cancer (26)

Cardiovascular Disease (10)

Infection (3)

Inflammation/Immunology (19)

Metabolic Disease (3)

Neurological Disease (11)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0678

Icaritin 5+ Cited Publications Anhydroicaritin	JAK Autophagy Apoptosis	Cancer
Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC₅₀ of 8 µM) and primary CML cells (IC₅₀ of 13.4 µM for CML-CP and 18 µM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings, also enhances osteogenesis ^[3.

HY-N0484

Liensinine Maximum Cited Publications 20 Publications Verification	Reactive Oxygen Species (ROS) Autophagy Apoptosis VEGFR JAK Amyloid-β p38 MAPK HIF/HIF Prolyl-Hydroxylase STAT PI3K JNK Akt	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Liensinine is a bisbenzylisoquinoline alkaloid. By inhibiting the PI3K/AKT and JNK/p38-MAPK signaling pathways, Liensinine suppresses autophagy and apoptosis, clears Aβ, and exerts anti-inflammatory, antioxidant and neuroprotective effects. Liensinine activates AMPK and inhibits the expression of HIF-1α and VEGF, thereby suppressing angiogenesis. Liensinine exerts anti-tumor effects through ROS-mediated inhibition of the *JAK2/STAT3* signaling pathway. Liensinine can be used for the research of diseases such as Alzheimer's disease, hepatocellular carcinoma, osteosarcoma, sepsis-induced organ injury and stroke .

HY-148748

Butyzamide 3 Publications Verification	JAK STAT p38 MAPK	Cardiovascular Disease
Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of platelets in mouse xenotransplantation assay .

HY-121471

Chrysoeriol 5+ Cited Publications	Endogenous Metabolite	Metabolic Disease
Chrysoeriol is a kind of natural yellow ash, which can be used for heating plants Coronopus didymus. Chrysoeriol suppresses the JAK2/STAT3, IκB/p65, and NF-κB pathways, and has strong anti-inflammatory activity .

HY-N2515

Ginsenoside Rk1 5+ Cited Publications	NF-κB PI3K JAK Apoptosis	Inflammation/Immunology Cancer
Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures . Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of *Jak2/Stat3* signaling pathway and NF-κB . Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis . Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .

HY-N1405

Cucurbitacin I 10+ Cited Publications Elatericin B; JSI-124; NSC-521777	STAT JAK	Cancer
Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity.

HY-N0635

Prim-O-glucosylcimifugin 4 Publications Verification	TNF Receptor NO Synthase COX	Inflammation/Immunology
Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and COX-2 expression by through regulating JAK2/STAT3 signaling.

HY-N1356

Reticuline 1 Publications Verification	JAK STAT NF-κB Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology
Reticuline shows anti-inflammatory effects through *JAK2/STAT3* and NF-κB signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3 . Reticuline exhibits cardiovascular effects .

HY-N0807

Swertiamarin 1 Publications Verification	MMP NF-κB JAK Keap1-Nrf2	Metabolic Disease Inflammation/Immunology Cancer
Swertiamarin is an orally active natural product with hypoglycemic, lipid-lowering, anti-rheumatic, and antioxidant activities. Swertiamarin can regulate the levels of pro-inflammatory cytokines, MMP, and NF-κB, and promote osteoblast proliferation. Swertiamarin has antioxidant and hepatoprotective effects against carbon tetrachloride induced rat liver toxicity through the Nrf2/HO-1 pathway. Swertiamarin can attenuate inflammatory mediators by regulating *JAK2/STAT3* transcription factors in adjuvant induced arthritis rats. Swertiamarin can be used in the research of diabetes and arthritis .

HY-N1535

Ponicidin 4 Publications Verification Rubescensine B	RIP kinase Apoptosis Reactive Oxygen Species (ROS) JAK STAT PI3K Akt Sirtuin Necroptosis Amyloid-β	Neurological Disease Cancer
Ponicidin (Rubescensine B) is an orally active RIPK1 inhibitor with a K_d value of 135 nM. Ponicidin inhibits the *JAK2/STAT3* pathway to induce apoptosis, activates the PI3K/Akt pathway, upregulates SIRT1 expression, alleviates oxidative stress, suppresses inflammatory responses and necroptosis, and blocks cell cycle progression. Ponicidin induces ROS production to exert antiproliferative and antiviral effects, while also improving cognitive function and reducing Aβ plaque deposition. Ponicidin can be used in studies related to hepatocellular carcinoma, Alzheimer's disease, and gastric cancer .

HY-100544

FLLL32 5+ Cited Publications	STAT JAK Apoptosis	Cancer
FLLL32, a synthetic analog of curcumina, is a *JAK2/STAT3* dual inhibitor with anti-tumor activity. FLLL32 can inhibit the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells .

HY-N2963

Broussonin E 2 Publications Verification	ERK p38 MAPK JAK STAT TNF Receptor Interleukin Related COX Arginase	Inflammation/Immunology
Broussonin E is a phenolic compound and shows anti-inflammatory activity. Broussonin E can suppress inflammation by modulating macrophages activation statevia inhibiting the ERK and p38 MAPK and enhancing *JAK2-STAT3* signaling pathway. Broussonin E can be used for the research of inflammation-related diseases such as atherosclerosis .

HY-113573

Protosappanin A PTA	Interleukin Related JAK STAT	Inflammation/Immunology
Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses *JAK2/STAT3*-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3 .

HY-146066

*α7 nAchR-JAK2-STAT3* agonist 1**	nAChR JAK STAT NO Synthase Interleukin Related	Inflammation/Immunology
α7 nAchR-JAK2-STAT3 agonist 1 is a potent α7 nAchR-JAK2-STAT3 agonist, with an IC₅₀ value of 0.32 μM for nitric oxide (NO). α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages. α7 nAchR-JAK2-STAT3 agonist 1 can inhibit LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 can be used for researching sepsis .

HY-112391

SD-1029 1 Publications Verification	JAK STAT	Cancer
SD-1029 is a *JAK2/STAT3* inhibitor . SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation .

HY-N0918

Desmethoxyyangonin Demethoxyyangonin; 5,6-Dehydrokavain	Monoamine Oxidase JAK IKK STAT NO Synthase Cytochrome P450	Neurological Disease Inflammation/Immunology
Desmethoxyyangonin is one of the six major kavalactones found in the Piper methysticum (kava) plant. Desmethoxyyangonin is a selective inhibitor of monoamine oxidase-B (MAO-B) (IC₅₀: 0.123 µM). Desmethoxyyangonin exerts anti-inflammatory effects by inhibiting Jak2/STAT3 and IKK signaling pathways. Desmethoxyyangonin induces CYP3A23 expression and leads to skeletal muscle relaxation .

HY-N2282

Zingiberen newsaponin Zingiberensis newsaponin	Aldose Reductase JAK STAT Autophagy Apoptosis NF-κB SOD Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Zingiberen Newsaponin (Zingiberensis newsaponin) is an orally active type of steroid saponin compound. Zingiberen Newsaponin exerts anti-hepatocellular carcinoma (HCC) effects by inhibiting autophagy and the *AKR1C1/JAK2/STAT3* pathway. Zingiberen Newsaponin activates oxidative stress (upregulates ROS and MDA) and mitochondrial pathways, promoting cancer cell apoptosis. Zingiberen Newsaponin alleviates cerebral ischemia-reperfusion (I/R) injury by decreasing the concentration of pro-inflammatory cytokines and inhibits NF-κB. Zingiberen Newsaponin can enhance the activity of SOD, eliminate free radicals and protect nerve cells. Zingiberen Newsaponin induces platelet aggregation .

HY-124858

SC99	STAT JAK Apoptosis	Cardiovascular Disease Cancer
SC99 is an orally active, selective *STAT3* inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling. SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities .

HY-N0885

Telocinobufagin 1 Publications Verification Telobufotoxin; Telocinobufogenin	JAK STAT mTOR PI3K Akt Polo-like Kinase (PLK) Na+/K+ ATPase Apoptosis Bacterial	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Telocinobufagin (Telobufotoxin; Telocinobufogenin) is an orally active bufadienolide with potential anti-tumor effects. Telocinobufagin exerts its anti-cancer effects on non-small cell carcinoma, osteosarcoma, thyroid cancer, breast cancer and head and neck squamous cell carcinoma by inhibiting the *STAT3, JAK2/STAT3, LARP1-mTOR, PI3K/Akt/Snail* and PLK1 pathways, and can also induce tumor cell apoptosis. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Telocinobufagin has a strong cardiac-stimulating effect by inhibiting the activity of Na ⁺/K ⁺-ATPase, and it can promote renal fibrosis. Telocinobufagin demonstrates non-opioid analgesic effects in various acute pain models .

HY-121471R

Chrysoeriol (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
Chrysoeriol (Standard) is the analytical standard of Chrysoeriol. This product is intended for research and analytical applications. Chrysoeriol is a kind of natural yellow ash, which can be used for heating plants Coronopus didymus. Chrysoeriol suppresses the JAK2/STAT3, IκB/p65, and NF-κB pathways, and has strong anti-inflammatory activity .

HY-146066A

*(R)-α7 nAchR-JAK2-STAT3* agonist 1**	nAChR JAK STAT NO Synthase	Others
(R)-α7 nAchR-JAK2-STAT3 agonist 1 is the R-enantiomer of α7 nAchR-JAK2-STAT3 agonist 1 (HY-146066). α7 nAchR-JAK2-STAT3 agonist 1 is a potent α7 nAchR-JAK2-STAT3 agonist, with an IC₅₀ value of 0.32 μM for nitric oxide (NO). α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages. α7 nAchR-JAK2-STAT3 agonist 1 can inhibit LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 can be used for researching sepsis .

HY-148748G

Butyzamide	JAK STAT p38 MAPK	Cardiovascular Disease
Butyzamide (GMP) is Butyzamide (HY-148748) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of platelets in mouse xenotransplantation assay .

HY-N5014

Liensinine perchlorate Maximum Cited Publications 20 Publications Verification	Reactive Oxygen Species (ROS) Autophagy Apoptosis VEGFR JAK Amyloid-β p38 MAPK HIF/HIF Prolyl-Hydroxylase STAT PI3K JNK Akt	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Liensinine perchlorate is a bisbenzylisoquinoline alkaloid. By inhibiting the PI3K/AKT and JNK/p38-MAPK signaling pathways, Liensinine perchlorate suppresses autophagy and apoptosis, clears Aβ, and exerts anti-inflammatory, antioxidant and neuroprotective effects. Liensinine perchlorate activates AMPK and inhibits the expression of HIF-1α and VEGF, thereby suppressing angiogenesis. Liensinine perchlorate exerts anti-tumor effects through ROS-mediated inhibition of the *JAK2/STAT3* signaling pathway. Liensinine perchlorate can be used for the research of diseases such as Alzheimer's disease, hepatocellular carcinoma, osteosarcoma, sepsis-induced organ injury and stroke .

HY-155746

JAK2-IN-9	JAK	Infection Inflammation/Immunology
JAK2-IN-9 (Compound A8) is a selective *JAK2* inhibitor (IC₅₀: 5 nM). JAK2-IN-9 inhibits the phosphorylation of JAK2, STAT3, and STAT5. JAK2-IN-9 has metabolic stabilities. JAK2-IN-9 induces apoptosis. JAK2-IN-9 can be used for research of myeloproliferative neoplasms (MPNs) .

HY-129341

WP1193	JAK STAT c-Myc	Neurological Disease Cancer
WP1193 is a novel *JAK2/STAT3* pathway inhibitor. WP1193 suppresses phosphorylation of *JAK2* and *STAT3. WP1193 decreases expression of stem cell markers including CD133* and c-myc. WP1193 can be used in the research of glioblastoma .

HY-N0678R

Icaritin (Standard) Anhydroicaritin (Standard)	JAK Reference Standards Autophagy Apoptosis	Cancer
Icaritin (Standard) is the analytical standard of Icaritin. This product is intended for research and analytical applications. Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC₅₀ of 8 μM) and primary CML cells (IC₅₀ of 13.4 μM for CML-CP and 18 μM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings, also enhances osteogenesis ^[2][3.

HY-131194

JAK2/STAT3-IN-1	Interleukin Related	Cancer
JAK2/STAT3-IN-1 (compound (S)-10a) is a potent GP130 inhibitor with an IC₅₀ of 3.04 µM. JAK2/STAT3-IN-1 shows anti-tumor activity .

HY-167839

*(R)-JAK2/STAT3-IN-1*	Apoptosis	Cancer
(R)-JAK2/STAT3-IN-1 is a GP130 D1 domain inhibitor with anti-tumor activity. (R)-JAK2/STAT3-IN-1 can inhibit the phosphorylation of JAK2 and STAT3. The affinity of (R)-JAK2/STAT3-IN-1 for GP130 protein is 3.8 μM. (R)-JAK2/STAT3-IN-1 effectively inhibits the viability and migration of tumor cells and promotes apoptosis .

HY-149647

HD-2a	JAK STAT	Inflammation/Immunology
HA-2a can inhibit the *JAK2/STAT3* pathway via downregulates circDcbld2 expression in RAW264.7 cells .

HY-N1405R

Cucurbitacin I (Standard) Elatericin B (Standard); JSI-124 (Standard); NSC-521777 (Standard)	STAT JAK Reference Standards	Cancer
Cucurbitacin I (Standard) is the analytical standard of Cucurbitacin I. This product is intended for research and analytical applications. Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity.

HY-183370

JAK2/STAT3-IN-2	JAK STAT Interleukin Related	Inflammation/Immunology
JAK2/STAT3-IN-2 is an orally active *JAK2/STAT3* inhibitor. JAK2/STAT3-IN-2 inhibits the phosphorylation of tyrosine residues in *JAK2* and *STAT3, blocks downstream signal transduction, disrupts the dimerization and nuclear translocation of STAT3, and suppresses pro-inflammatory transcriptional activity. JAK2/STAT3-IN-2* inhibits the expression of IL-17A and IL-17F, reduces immune cell infiltration, and inhibits the production of NO simultaneously. JAK2/STAT3-IN-2 exerts a protective effect in a mouse model of ulcerative colitis induced by DSS (HY-116282C). JAK2/STAT3-IN-2 can be used for the research of ulcerative colitis .

HY-N0635R

Prim-O-glucosylcimifugin (Standard)	TNF Receptor Reference Standards NO Synthase COX	Inflammation/Immunology
Prim-O-glucosylcimifugin (Standard) is the analytical standard of Prim-O-glucosylcimifugin. This product is intended for research and analytical applications. Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and COX-2 expression by through regulating JAK2/STAT3 signaling.

HY-155807

DPP	STAT JAK Apoptosis	Cancer
DPP is a Platinum(IV) complex, bearing pterostilbene-derived axial ligand. DPP inhibit the JAK2-STAT3 pathway in breast cancer (BC) cells with antiproliferative activity, and activates caspase-3 and cleaved poly ADP-ribose polymerase to induces apoptosis. DPP promotes the maturation and antigen presentation of dendritic cells, and exhibits in vivo safety .

HY-N13294

Cernuumolide J TMJ-105	Apoptosis JAK STAT p38 MAPK JNK ERK	Cancer
Cernuumolide J (TMJ-105) is an *JAK2/STAT3* inhibitor. Cernuumolide J induces G2/M phase arrest and apoptosis in HEL leukemia cells by downregulating the phosphorylation of *JAK2, STAT3*, and Erk, and activating the phosphorylation of JNK and p38 MAPK. Cernuumolide J inhibits HEL leukemia cell growth in a time- and concentration-dependent manner, with an IC₅₀ value of 1.79 μM. Cernuumolide J can be used for research in the field of anti-cancer therapy .

HY-N0918R

Desmethoxyyangonin (Standard) Demethoxyyangonin (Standard); 5,6-Dehydrokavain (Standard)	Reference Standards Monoamine Oxidase JAK STAT NO Synthase IKK Cytochrome P450	Neurological Disease Inflammation/Immunology
Desmethoxyyangonin (Standard) is one of the six major kavalactones found in the Piper methysticum (kava) plant. Desmethoxyyangonin (Standard) is a selective inhibitor of monoamine oxidase-B (MAO-B) (IC₅₀: 0.123 µM). Desmethoxyyangonin (Standard) exerts anti-inflammatory effects by inhibiting Jak2/STAT3 and IKK signaling pathways. Desmethoxyyangonin (Standard) induces CYP3A23 expression and leads to skeletal muscle relaxation .

HY-155808

STAT3-IN-18	STAT JAK Apoptosis COX	Cancer
STAT3-IN-18 (compound SPP) is a platinum (IV) complex with an axial ligand derived from sandalwood. STAT3-IN-18 inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, with anti-proliferative activity. STAT3-IN-18 activates caspase-3 and increases cleaved polyADP-ribose polymerase to induce apoptosis. STAT3-IN-18 promotes maturation and antigen presentation of dendritic cells and demonstrates safety in vivo.

HY-125542

DCZ3301	Apoptosis JAK STAT ERK PI3K Akt	Cancer
DCZ3301 is an apoptosis inducer. DCZ3301 modulates *JAK2/STAT3, ERK1/2, and PI3K/AKT* pathways. DCZ3301 induces G2/M and M phase cell cycle arrest and inhibits cell proliferation and viability. DCZ3301 enhances DNA damage, inhibits DNA repair, and suppresses angiogenesis. DCZ3301 can be used for the research of diffuse large B-cell lymphoma, multiple myeloma and leukemia/lymphoma .

HY-N2515R

Ginsenoside Rk1 (Standard)	Reference Standards NF-κB PI3K JAK Apoptosis	Inflammation/Immunology Cancer
Ginsenoside Rk1 (Standard) is the analytical standard of Ginsenoside Rk1. This product is intended for research and analytical applications. Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures . Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB . Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis . Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .

HY-N0484R

Liensinine (Standard)	Reference Standards Reactive Oxygen Species (ROS) Autophagy Apoptosis VEGFR JAK Amyloid-β p38 MAPK HIF/HIF Prolyl-Hydroxylase STAT PI3K JNK Akt	Cardiovascular Disease Neurological Disease Cancer
Liensinine (Standard) is the analytical standard of Liensinine (HY-N0484). This product is intended for research and analytical applications. Liensinine is a bisbenzylisoquinoline alkaloid. By inhibiting the PI3K/AKT and JNK/p38-MAPK signaling pathways, Liensinine suppresses autophagy and apoptosis, clears Aβ, and exerts anti-inflammatory, antioxidant and neuroprotective effects. Liensinine activates AMPK and inhibits the expression of HIF-1α and VEGF, thereby suppressing angiogenesis. Liensinine exerts anti-tumor effects through ROS-mediated inhibition of the *JAK2/STAT3* signaling pathway. Liensinine can be used for the research of diseases such as Alzheimer's disease, hepatocellular carcinoma, osteosarcoma, sepsis-induced organ injury and stroke .

HY-158439

anti-TNBC agent-7	JAK STAT	Cancer
anti-TNBC agent-7 (Compound 13c) possesses anticancer activity, serving as a molecular probe to recognize and regulate the signal transduction of the *USP21/JAK2/STAT3* axis, exhibiting nanomolar-level cytotoxicity against MDA-MB-231 and HCC-1806 cancer cells, effectively combating triple-negative breast cancer (TNBC) .

HY-N15564

Theleganbanin B	Drug Derivative	Neurological Disease Inflammation/Immunology
Theleganbanin B is a p-terphenyl derivative found in the Thelephora ganbajun. Theleganbanin B inhibits TNF-α, IL-6, and IL-1β production in LPS-induced BV-2 microglial cells. Theleganbanin B inhibits the phosphorylation of JAK2/STAT3. Theleganbanin B is promising for research of neurodegenerative diseases .

HY-183272

PI3K/Akt/mTOR-IN-7	Akt mTOR JAK STAT Apoptosis Caspase Reactive Oxygen Species (ROS) NO Synthase	Cardiovascular Disease Neurological Disease
PI3K/Akt/mTOR-IN-7 is an AKT/mTOR and *JAK2/STAT3* inhibitor. PI3K/Akt/mTOR-IN-7 restores p-Akt, p-mTOR, and *p-STAT3* expression, reduces pro-apoptotic Caspase-3 mRNA expression. PI3K/Akt/mTOR-IN-7 reduces intracellular ROS accumulation and inhibits NO production. PI3K/Akt/mTOR-IN-7 can be used for research on stroke, Alzheimer's disease and Parkinson's disease .

HY-183670

JAK2-IN-21	JAK STAT Apoptosis	Infection Cancer
JAK2-IN-21 is a Janus kinase 2 (JAK2) inhibitor with an IC₅₀ of 12.25 nM. JAK2-IN-21 inhibits the *JAK2/STAT3/STAT5* tumor-promoting signaling pathway and reduces *JAK2* protein expression. JAK2-IN-21 exhibits selective cytotoxicity against HPV-positive cancer cells and induces cancer cell apoptosis. JAK2-IN-21 can be used in the research of HPV-positive cervical cancer .

HY-180561

WWQ-03-012	Deubiquitinase JAK STAT Apoptosis	Cancer
WWQ-03-012 is a selective deSUMOylating isopeptidases DESI2 inhibitor with an IC₅₀ of 47.3 μM. WWQ-03-012 cans induce JAK2-V617F ubiquitination-proteasome degradation with no significant effect on wild-type JAK2. WWQ-03-012 can block *JAK2-STAT3/5* signaling, inhibit cell proliferation and induce apoptosis. WWQ-03-012 has a synergistic effect in combination with Ruxolitinib (HY-50856), further enhancing its killing effect on JAK2 mutant cells. WWQ-03-012 can be used for the research of cancer, such as myeloproliferative neoplasms .

Butyzamide	Fluorescent Dyes
Butyzamide (GMP) is Butyzamide (HY-148748) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of platelets in mouse xenotransplantation assay .

Cat. No.	Product Name	Category	Target	Chemical Structure